Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
---|---|---|---|---|---|---|
Filed 2022-03-18 12:28 Tx date 2022-03-15 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Restricted Stock Units
56 - Grant of rights
|
+44,536 vol |
44,536 | |
Filed 2022-03-18 12:27 Tx date 2022-03-15 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
50 - Grant of options
|
$4,850
+10,000 vol $0.485 each |
180,000 | |
Filed 2021-11-22 14:22 Tx date 2021-09-15 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$13,890
+44,536 vol $0.3119 each |
2,431,089 | |
Filed 2021-11-22 14:21 Tx date 2021-09-15 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-13,890.7784
-44,536 vol $0.3119 each |
2,386,553 | |
Filed 2021-11-22 14:20 Tx date 2021-09-15 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$13,890
+44,536 vol $0.3119 each |
||
Filed 2021-11-22 14:20 Tx date 2021-05-19 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$-17,974.7296
-44,536 vol $0.4036 each |
2,386,553 | |
Filed 2021-11-22 14:19 Tx date 2021-05-19 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
30 - Acquisition or disposition under a purchase/ownership plan
|
$17,974
+44,536 vol $0.4036 each |
2,431,089 | |
Filed 2021-11-22 14:15 Tx date 2021-09-15 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Restricted Stock Units
57 - Exercise of rights
|
-44,536 vol |
0 | |
Filed 2021-11-22 14:14 Tx date 2021-09-15 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Restricted Stock Units
56 - Grant of rights
|
+44,536 vol |
44,536 | |
Filed 2021-11-22 14:09 Tx date 2021-03-15 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Restricted Stock Units
56 - Grant of rights
|
+44,536 vol |
44,536 | |
Filed 2021-11-22 14:08 Tx date 2021-05-19 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Restricted Stock Units
57 - Exercise of rights
|
-44,536 vol |
0 | |
Filed 2021-11-22 14:06 Tx date 2021-03-15 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Restricted Stock Units
56 - Grant of rights
|
+44,536 vol |
||
Filed 2021-11-22 14:05 Tx date 2018-10-01 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Restricted Stock Units
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2021-11-22 13:47 Tx date 2021-11-19 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-86,520.4818
-359,603 vol $0.2406 each |
2,026,950 | |
Filed 2021-11-22 13:45 Tx date 2021-09-15 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
50 - Grant of options
|
$4,850
+10,000 vol $0.485 each |
170,000 | |
Filed 2021-11-22 13:44 Tx date 2021-03-15 |
$LABS
MediPharm Labs Corp. |
Everitt, Warren
4 - Director of Issuer, 7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
50 - Grant of options
|
$4,850
+10,000 vol $0.485 each |
160,000 | |
Filed 2020-11-03 16:33 Tx date 2020-10-08 |
$LABS
MediPharm Labs Corp. (formerly POCML 4 Inc.) |
Everitt, Warren
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$1,999,999
+2,359,603 vol $0.85 each |
2,386,553 | |
Filed 2019-11-21 17:01 Tx date 2018-10-01 |
$LABS
MediPharm Labs Corp. (formerly POCML 4 Inc.) |
Everitt, Warren
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
26,950 | ||
Filed 2019-11-21 16:52 Tx date 2018-10-01 |
$LABS
MediPharm Labs Corp. (formerly POCML 4 Inc.) |
Everitt, Warren
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
150,000 |